NTRA, US6323071042

Natera stock: November 5 results date matters for Natera stock

Published on 10/20/2026 at 17:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Revenue reached USD 752.75 million in the second quarter. Natera stock costs EUR 360.10 on October 20, 2026, up 0.03 percent versus the Xetra close.

Reporting date and growth

  • Natera's next earnings date is November 5, 2026.
  • Second-quarter revenue reached USD 752.75 million after rising 37.70 percent.
  • Natera stock costs EUR 360.10 at Lang & Schwarz on October 20, 2026 at 5:01 p.m. CEST, 0.03 percent above the Xetra close of October 19, 2026.
NTRA, US6323071042, Illustration mit AI erstellt.

Natera (ISIN US6323071042) is scheduled to report its third-quarter results on November 5, 2026, after the market closes, according to MarketBeat. Natera was trading at EUR 360.10 at Lang & Schwarz on October 20, 2026 at 5:01 p.m. CEST, up 0.03 percent versus the Xetra close of October 19, 2026.

Revenue growth sets the baseline

The scheduled report follows a second quarter in which revenue reached USD 752.75 million, according to MarketBeat. That figure was 37.70 percent above the prior-year quarter, while the adjusted loss amounted to USD 0.47 per share against a consensus loss of USD 0.49 per share. The comparison gives the November report a clear benchmark: investors will be able to measure whether growth remains ahead of expectations while losses narrow.

Nasdaq price stays below its high

On Nasdaq, Natera was trading at USD 405.49 on October 20, 2026 at 11:03 a.m. ET. The quote stood between a 52-week low of USD 181.00 and a 52-week high of USD 437.41, leaving the stock 7.30 percent below its high. Market capitalization was USD 58.4 billion at that timestamp, while the day's range ran from USD 396.09 to USD 405.86.

What does November 5 mean?

The date creates the next measurable checkpoint for Natera's diagnostics business. Its investor-relations overview describes a portfolio centered on cell-free DNA testing in women's health, oncology and organ health, including Panorama, Signatera and Prospera, according to Natera. The second-quarter revenue base of USD 752.75 million and the consensus loss of USD 0.49 per share provide two concrete reference points for the upcoming release.

Price and reporting date

The euro quotation was nearly unchanged against the Xetra close, while the US quote was 7.30 percent below its 52-week high. The November 5, 2026 reporting date is the next scheduled corporate event identified for Natera.

Natera stock was trading at EUR 360.10 at Lang & Schwarz on October 20, 2026 at 5:01 p.m. CEST, 0.03 percent above the Xetra close of October 19, 2026 at EUR 360.00. The Nasdaq quote was USD 405.49 on October 20, 2026 at 11:03 a.m. ET.

The further course of trading is shown by the continuously updated real-time quote of Natera stock.

Natera stock key facts

  • Company: Natera, Inc.
  • ISIN: US6323071042
  • Ticker: NTRA
  • Primary exchange: Nasdaq
  • Price Lang & Schwarz (as of October 20, 2026, 5:01 p.m. CEST): EUR 360.10
  • Change versus Xetra close: plus 0.03 percent
  • Xetra close (October 19, 2026): EUR 360.00
  • Market capitalization: USD 58.4 billion (as of October 20, 2026)
  • 52-week range: USD 181.00-437.41 (as of October 20, 2026)
  • Sector / Industry: Healthcare / Medical Diagnostics and Research
  • Next earnings date: November 5, 2026

Market context: Market report S&P 500.

More news and analyses on Natera stock

Disclaimer...
en | US6323071042 | NTRA | boerse | 70375422 | bgmi